Item does not contain fulltextUsing data from ARISTOTLE, we describe the periprocedural management of anticoagulation and rates of subsequent clinical outcomes among patients chronically anticoagulated with warfarin or apixaban. We recorded whether (and for how long) anticoagulant therapy was interrupted preprocedure, whether bridging therapy was used, and the proportion of patients who experienced important clinical outcomes during the 30 days postprocedure. Of 10 674 procedures performed during follow-up in 5924 patients, 9260 were included in this analysis. Anticoagulant treatment was not interrupted preprocedure 37.5% of the time. During the 30 days postprocedure, stroke or systemic embolism occurred after 16/4624 (0.35%) procedures amo...
BACKGROUND: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban ...
BACKGROUND: A novel approach to determine the effect of a treatment is to calculate the delay of eve...
Background: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban ...
BACKGROUND: We sought to assess the occurrence of events after blinded study drug discontinuation an...
BACKGROUND: We sought to assess the occurrence of events after blinded study drug discontinuation an...
Item does not contain fulltextBACKGROUND: We sought to assess the occurrence of events after blinded...
Item does not contain fulltextAIM: In the Apixaban for Reduction in Stroke and Other Thromboembolic ...
Item does not contain fulltextBACKGROUND: In the ARISTOTLE trial, the rate of stroke or systemic emb...
AIM: In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation ...
AIM: In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation ...
Contains fulltext : 202664.pdf (Publisher’s version ) (Closed access)Warfarin is d...
Contains fulltext : 165742.pdf (publisher's version ) (Open Access)OBJECTIVE: To d...
Contains fulltext : 190525.pdf (publisher's version ) (Closed access)BACKGROUND: W...
Aim In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (...
The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in n...
BACKGROUND: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban ...
BACKGROUND: A novel approach to determine the effect of a treatment is to calculate the delay of eve...
Background: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban ...
BACKGROUND: We sought to assess the occurrence of events after blinded study drug discontinuation an...
BACKGROUND: We sought to assess the occurrence of events after blinded study drug discontinuation an...
Item does not contain fulltextBACKGROUND: We sought to assess the occurrence of events after blinded...
Item does not contain fulltextAIM: In the Apixaban for Reduction in Stroke and Other Thromboembolic ...
Item does not contain fulltextBACKGROUND: In the ARISTOTLE trial, the rate of stroke or systemic emb...
AIM: In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation ...
AIM: In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation ...
Contains fulltext : 202664.pdf (Publisher’s version ) (Closed access)Warfarin is d...
Contains fulltext : 165742.pdf (publisher's version ) (Open Access)OBJECTIVE: To d...
Contains fulltext : 190525.pdf (publisher's version ) (Closed access)BACKGROUND: W...
Aim In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (...
The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in n...
BACKGROUND: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban ...
BACKGROUND: A novel approach to determine the effect of a treatment is to calculate the delay of eve...
Background: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban ...